Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneus Ltd. ( (AU:CMB) ) has shared an update.
Cambium Bio Limited announced a correction to a previously lodged Change of Director’s Interest Notice for Mr. Terrence Walts, clarifying that the correct date of change is 16 October 2025. This correction reflects the issuance of securities following shareholder approval at the company’s 2025 Annual General Meeting, ensuring accurate records and transparency for stakeholders.
More about Regeneus Ltd.
Cambium Bio Limited is a Sydney-based clinical-stage regenerative medicine company specializing in the development of innovative biologics for ophthalmology and tissue repair applications. The company leverages its proprietary technology based on human platelet lysate to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular®, is aimed at addressing unmet medical needs in the treatment of dry eye disease, while its stem cell platform, Progenza™, is being developed for knee osteoarthritis and other tissue repair indications.
Average Trading Volume: 19,220
Technical Sentiment Signal: Sell
Current Market Cap: A$11.02M
Learn more about CMB stock on TipRanks’ Stock Analysis page.